Rekombinanter TNFRSF8 (Brentuximab Biosimilar) Antikörper
Reaktivität: Human
ELISA, BLI, FACS, Func, SPR
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle TNFRSF8 (Brentuximab Biosimilar) Produkte
- TNFRSF8 (Brentuximab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
- Expressionssystem
- CHO Cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser TNFRSF8 (Brentuximab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
- Verwendungszweck
- Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab)
- Sequenz
- QIQLQQSGPE VVKPGASVKI SCKASGYTFT DYYITWVKQK PGQGLEWIGW IYPGSGNTKY NEKFKGKATL TVDTSSSTAF MQLSSLTSED TAVYFCANYG NYWFAYWGQG TQVTVSAAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG,DIVLTQSPAS LAVSLGQRAT ISCKASQSVD FDGDSYMNWY QQKPGQPPKV LIYAASNLES GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPW TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
- Produktmerkmale
- Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.38 kDa.
- Reinheit
- >95 %
- Isotyp
- IgG1
-
anti-TNFRSF8 (Brentuximab Biosimilar) antibody
Research Grade Reaktivität: Human ELISA Wirt: Maus Chimeric unconjugated Recombinant Antibody
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Therapeutic Agents by Target and Mechanism: CD30 inhibitors
Conditions: Anaplastic Large Cell Lymphoma Hematologic malignancies Hodgkin Lymphoma
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- +4°C,-80°C
-
- Target
- TNFRSF8 (Brentuximab Biosimilar)
- Abstract
- TNFRSF8 (Brentuximab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
- Synonyms: TNFRSF8
- Molekulargewicht
- 145.38 kDa
- UniProt
- P28908
-
Sie sind hier:
